Market revenue in 2024 | USD 646.5 million |
Market revenue in 2030 | USD 504.5 million |
Growth rate | -4.3% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.97% in 2024. Horizon Databook has segmented the France anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
France’s anti-VEGF therapeutics market is expected to witness growth over the forecast period, owing to research initiatives such as Treatand-Extend dosing regimen, coupled with the rise in disease burden in the country. According to European Society of Retina Specialists (EURETINA) report 2018, an estimated 150,000 people were affected by retinal vein occlusions.
Moreover, favorable reimbursement for treatment is expected to support market growth. In France, one vial of medication per patient is used & fully reimbursed; however, splitting of vials is not allowed, due to which, ophthalmologists are reluctant to use such products.
By the end of May 2020, Eylea prefilled syringes were made available in France. This novel formulation can enable ophthalmologists to introduce the medication more efficiently, increasing its adoption.
Horizon Databook provides a detailed overview of country-level data and insights on the France anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into France anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account